Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Astion Pharma strengthens capital base by DKK 50 million


Astion Pharma, a company focusing on developing therapeutic products for the treatment of skin diseases, is experiencing very strong developments and has achieved significant and favourable results in several of the Company’s development projects. The Company currently has three development projects in Phase II clinical studies for the treatment of hand dermatitis, seboroic dermatitis and cutaneous lupus in addition to a large portfolio of product candidates and research programmes in earlier phases.
“This capital increase supports our goal of advancing the development of our projects as much as possible in order to increase their value,” said Henrik Moltke, CFO of Astion Pharma. “We intend to wait until late in the development process or in connection with regulatory approval of a new drug to decide whether sales and marketing should be handled in house or wholly or partially by a licensee,” he continued.
Contact person: Henrik Moltke, CFO
Tel: +45 2244 5404
E-mail: hkm@astion.com
Astion Pharma A/S develops pharmaceutical products for the treatment of skin diseases. It is estimated that one person in four worldwide will suffer from a skin diseases sometime in life, causing a deterioration of their quality of life. It is the Company’s goal to become a leading player in the treatment of skin diseases for which there is currently a major need for new and better therapies. Astion Pharma has a strong platform of proprietary technologies for the development of new and innovative products. The Company pursues development activities through a strong international network of scientific partners and leading contract research organisations. The Company currently has three development projects in Phase II clinical studies in hand dermatitis, seboroic dermatitis and cutaneous lupus in addition to a large portfolio of product candidates and research programmes in earlier phases. For additional information please visit our web site: www.astion.com.
.


Publisher Contact Information:

Astion Pharma A/S
+45 22445404
hkm@astion.com

Company profile of Astion Pharma A/S
Past press releases of Astion Pharma A/S.

Data


27,526
Tech investments
From our Online Data Service
17,759
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 25€24.0MInternet commerce
Nov 8N/AOther Computers & Electronics
Nov 5€2.1MAudio/Video
Nov 5€5.2MOther Computers & Electronics
Nov 5€0.4MInternet services
Nov 5€1.3MSecurity
Nov 5€1.5MAudio/Video

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Sep 30
TetaVi
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Mar 31
CompPair
the fit allocates chf 100'000 to comppair technologies

Jan 29
Yumpingo
yumpingo raises $10m to transform guest experiences in restaurants





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.